Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Air France-KLM Q3 Adjusted Operating Profit Rises 10% to EUR 1.35 Billion

Air France-KLM Q3 Adjusted Operating Profit Rises 10% to EUR 1.35 Billion

BitgetBitget2026/11/05 06:59
  • Air France-KLM’s third-quarter 2026 adjusted operating profit rose 10% year over year to EUR 1.35 billion.
  • Revenues climbed 8% to EUR 9.92 billion, with stronger unit revenues fully offsetting higher fuel prices.
  • Nine-month recurring adjusted operating free cash flow jumped 73% year over year to EUR 1.35 billion, primarily supported by improved net capital expenditures.
  • KLM announced additional restructuring measures covering fleet simplification, organizational changes and more competitive labor agreements.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Air France-KLM SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050158OMX_____CNEWS_EN_GNW1001301924_en) on November 05, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss